2025

Future Vision Forum

Immunomodulation
Cancer
Aging

Thursday, September 18-19
Franklin Institute
Philadelphia, Pennsylvania

FUTURE VISION FORUM

2025
Future Vision Forum
Immunomodulation, Cancer & Aging

Contents

Click the Future Vision Forum Logo to Return to the Table of Contents or Attendee List

Future Vision Foundation

FUTURE VISION FORUM

Future Vision Forum
Thursday, September 18, 2025

Program

7:30/7:45	**Pick up from Hotel by Trolley**
8:00-8:30	Faculty Arrive – Levitt & Gershman Conference Center, Franklin Institute
8:30-8:35	Welcome and Introduction – Suber Huang
8:35-10:10	**Session 1 – Immunotherapy I**
8:35-8:50	Overview – JP Dunn
8:50-10:10	Discussion – Moderators: JP Dunn, Suber Huang
10:10-10:30	Break
10:30-12:00	**Session 2 – Immunotherapy II**
10:45-12:00	Discussion – Moderators: JP Dunn, Suber Huang
12:00 – 1:00	**Lunch – Patio**
1:00-2:20	**Session 3 – Cancer I**
1:00-1:05	Recognition of Dr. Jerry Shields, Distinguished Lecture Introduction – S Huang
1:05-1:25	**Distinguished Lecture – Dr. Carol Shields**
1:25-2:25	Discussion – Carol Shields, Suber Huang
2:25-2:40	Break
2:40-4:00	**Session 4 – Cancer II**
2:35-4:00	Discussion – Moderators: Carol Shields, Suber Huang
4:00-4:10	Day 1 Review, Preview of Day 2
4:10	**Adjourn**
4:30	**Return to Hotel – Trolley Provided**
6:00 -6: 45	**Cocktail Hour - Salon II at Courtyard by Marriott**
6:40 sharp	**Group Photo – Abele Library at Courtyard by Marriott**
7:00- 9:00	**Gala Dinner – Abele Library at Courtyard by Marriott**

Future Vision Foundation

FUTURE VISION FORUM

Future Vision Forum
Friday, September 19, 2025

Program

8:00/ 8:15	**Pick up from Hotel by Trolley**
8:30-8:35	Introduction – S Huang
8:35-10:10	**Session 5 – Aging/Retinal Degeneration I**
8:35-8:50	Overview – Dr. Jose Alain Sahel
8:50-10:10	Discussion – Moderators: Jose Alain Sahel, Suber Huang
10:10-10:25	Break
10:25-12:00	**Session 6 – Aging/Retinal Degeneration II**
10:25-12:00	Discussion – Moderators: Jose Alain Sahel, Suber Huang
12:00 – 1:00	**Lunch – Patio**
1:00-2:00	**Session 7 – Industry Perspectives**
1:00-1:05	Introduction – S Huang
1:05-1:25	Bausch and Lomb
1:25-1:45	Aura Biosciences
1:45-2:05	Apellis
2:05-3:45	**Forecasting the Future, Unmet Needs, Takeaways, Strategic Directions** **Moderator: Suber Huang**
3:45-3:55	**Closing remarks, acknowledgments**
4:00	**Adjourn**

Save the Date: August 2026 Future Vision Forum:
Vision Restoration: The Biology - Machine Interface
San Francisco, CA

Future Vision Foundation

FUTURE VISION FORUM

2025
Future Vision Forum
Immunomodulation, Cancer & Aging

Attendees

Mayssa Attar, PhD
Bausch & Lomb

Jacobi Cunningham, PhD
Apellis

Christine Curcio, PhD
University of Alabama, Birmingham

James P Dunn, PhD
Wills Eye Institute

Daniela Ferrara, MD, MS, PhD
TopCon

James Handa, MD
Johns Hopkins University

Jill Hopkins, MD
Aura Biosciences

Suber Huang, MD, MBA
Retina Center of Ohio/ Future Vision Foundation

Szilard Kiss, MD
Cornell University

Jennifer Lim, MD
University of Illinois

Keith Luhrs, PhD
Bausch & Lomb

Prithvi Mruthyunjaya, MD, MHS
Stanford University

Marlana Orloff- Dacey, MD
Thomas Jefferson University

Xianne Penny, PhD, NREMT
Aura Biosciences

Stephen Poor, MBBS MRCOphth
Apellis

SriniVas Sadda, MD
University of California, Los Angeles

Jose Alain Sahel, MD
University of Pittsburgh

Takami Sato, MD, PhD
Thomas Jefferson University

Rino Seedor, MD
Thomas Jefferson University

Carol Shields, MD
Wills Eye Institute

Mandeep Singh, MD, PhD
Johns Hopkins University

Jennifer Thorne, MD, PhD
Johns Hopkins University

Demetrios G Vavvas, MD, PhD
Harvard University

Future Vision Foundation

Contact Information

Mayssa.attar@bausch.com

Bausch & Lomb

References

- Luu KT, Seal J, Green M, Winskill C, Attar M. Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis. J Clin Pharmacol. 2022 May;62(5):594-608. doi: 10.1002/jcph.2002. Epub 2022 Jan 5. PMID: 34783362; PMCID: PMC9305109.

- Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:; Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE, Thorne JE, Altaweel MM, Kempen JH, Jabs DA. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. doi: 10.1016/j.ophtha.2023.04.011. Epub 2023 Jun 13. PMID: 37318415; PMCID: PMC10524707.

- Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group; Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May;132(5):527-537. doi: 10.1016/j.ophtha.2024.11.021. Epub 2024 Nov 28. PMID: 39612949; PMCID: PMC12018142.

FUTURE VISION FORUM

Mayssa Attar, PhD

Senior Vice President
Pharmaceutical and Consumer R&D Head

Narrative Biography

Mayssa Attar is an accomplished executive with more than two decades of leadership experience in the biopharmaceutical and device industries. As a translational scientist, she has made significant contributions to the development, registration and/or commercialization of more than a dozen approved therapies across multiple disease areas. She joined Bausch and Lomb in May 2023 in the role of Senior Vice President, Global Pharmaceutical and Consumer Product R&D Head. Since joining B+L, she has led the transformation of the pipeline via capability build and internal and external scientific efforts. Prior to her current role, Mayssa spent 3 years at AbbVie as the Vice President of Research, Nonclinical and Translational Sciences Eye Care, Neurotoxins and Aesthetics at AbbVie. At AbbVie, Mayssa was awarded the title of Senior Research Fellow in recognition of her scientific contributions to advance science for patients. Mayssa began her industry career at Allergan where she spent more than 20 years and assumed roles of increasing responsibility where she became the Global Head of Nonclinical and Clinical Pharmacology overseeing the entire portfolio. Dr. Attar has over 30-peer reviewed publications, more than 10 issued patents and is an invited national and international speaker. Mayssa has serves as adjunct faculty at USC School of Pharmacy and as a board member for Character Bio. She has served as a board member of the Allergan Foundation and the Greater Irvine Chamber of Commerce. Dr. Attar earned her Bachelor of Science with Honors and Masters of Science in Biochemistry from the University of Ottawa, Canada. Under the mentorship of Vincent HL Lee, a pioneer in drug delivery, Mayssa earned her PhD in Pharmaceutical Sciences from the University of Southern California. Mayssa is a Diplomate of the American Board of Toxicology.

Future Vision Foundation

Contact Information

Jacobi .Cunningham@apellis.com

Apellis

References

- Codagnone MG, Kara N, Ratsika A, Levone BR, van de Wouw M, Tan LA, Cunningham JI, Sanchez C, Cryan JF, O'Leary OF. Inhibition of FKBP51 induces stress resilience and alters hippocampal neurogenesis. Mol Psychiatry. 2022 Dec;27(12):4928-4938. doi: 10.1038/s41380-022-01755-9. Epub 2022 Sep 14. PMID: 36104438; PMCID: PMC9763121.

- Puryear CB, Brooks J, Tan L, Smith K, Li Y, Cunningham J, Todtenkopf MS, Dean RL, Sanchez C. Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? Neurosci Biobehav Rev. 2020 Jan;108:658-678. doi: 10.1016/j.neubiorev.2019.12.007. Epub 2019 Dec 9. PMID: 31821832.

- Smith KL, Cunningham JI, Eyerman DJ, Dean RL 3rd, Deaver DR, Sanchez C. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat. Neuropharmacology. 2019 Mar 1;146:316-326. doi: 10.1016/j.neuropharm.2018.11.015. Epub 2018 Nov 15. PMID: 30448421.

FUTURE VISION FORUM

Jacobi Cunningham, PhD

Program Lead, Ophthalmology
Director, Pharmacology and Scientific Operations
Translational Research

Narrative Biography

Over 15 years of experience in neuroscience research including10 years of applied research and small molecule drug discovery inpsychiatric illness, pain pharmacology and drug abuse disorders.Experienced in leading diverse cross functional teams of junior andsenior scientists to guide drug discovery and development programs.Significant data and regulatory contributions to multiple late stageclinical development and discovery programs. Strong interpersonalskills leading to successful participation in collaborative researchteams as well as the ability to manage and complete independentprojects. Expertise in a wide variety of in vivo, in vitro and molecularbiology techniques encompassing neurochemistry, functionalneuropharmacology and behavioral models in rodents. Excellentwritten and oral communication skills demonstrated through regulardepartmental presentations, scientific publications and conferencepresentations/abstracts.

Future Vision Foundation

Contact Information

Cacurcio@gmail.com

University of Alabama at Birmingham

References

- Curcio CA, Mullins RF, Stone EM, Goerdt L, Kar D, Gao L, McGwin G Jr, Owsley C. Genetic Associations of Rod- and Cone-Mediated Vision in Aging and Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):50. doi: 10.1167/iovs.66.9.50. PMID: 40673740; PMCID: PMC12282642.

- Wang Z, Anderson DMG, Messinger JD, Curcio CA, Schey KL. Glycolipids implicated as mediators of clinically visible retinal pigment epithelial migration in age-related macular degeneration. Proc Natl Acad Sci U S A. 2025 Jul 22;122(29):e2503191122. doi: 10.1073/pnas.2503191122. Epub 2025 Jul 14. PMID: 40658846; PMCID: PMC12305059.

- Hammer M, Oertel J, Alderzy H, Tarhan M, Meller D, Curcio CA. Fundus autofluorescence intensity, lifetime, and spectral imaging in age-related macular degeneration. Exp Eye Res. 2025 Sep;258:110500. doi: 10.1016/j.exer.2025.110500. Epub 2025 Jun 26. PMID: 40581140.

FUTURE VISION FORUM

Christine Curcio, PhD

Professor Emeritus: Director of the AMD Histopathology Lab

Narrative Biography

Christine A. Curcio PhD, a neuroscientist by training, has made seminal contributions to the anatomic and molecular pathobiology of age-related macular degeneration (AMD), which degrades central vision in aged adults worldwide. Using tools of digital histology and collaborating with innovative eye banks, her laboratory has made multiple top-level discoveries about human retina and AMD. These studies support diagnostic techniques for ophthalmology, including optical coherence tomography, rod-mediated dark adaptation, blue/two-wavelength autofluorescence, and adaptive optics assisted imaging.In 1984-96, she contributed the first 2-dimensional continuous maps of photoreceptors in normal human retina. These established the dominance of rods in the macula lutea and loss of parafoveal rods as a major feature of aging and in AMD. These studies provided visualization targets for single-cell imaging and spurred the development of rod-mediated dark adaptation as a functional indicator for the onset and early progression of AMD.

In 1998-2011 she focused on the ultrastructure, composition, and biologic context of soft drusen, AMD's major intraocular risk factor, finding that lipoproteins of intraocular origin were a major component (since confirmed in animal models) and highest in central retina.

From 2009 to present, she created Project MACULA (http://projectmacula), an online digital microscope for annotated high-resolution AMD histopathology. With expert clinical collaborators (Spaide, Freund), she described for the first time or most comprehensively histologic correlates to AMD OCT features, including extracellular deposits, gliosis, RPE transdifferentiation, neovascularization variants, and atrophy.

Dr. Curcio has >319 PubMed entries, >37,837 citations, and a lifetime H-index of 95. She received the 2002 (inaugural) Roger H. Johnson Prize for Macular Degeneration research, 2014 Ludwig von Sallmann Prize, 2020 Research to Prevent Blindness – David F. Weeks Award, and the 2022 Lawrence A. Yannuzzi Lectureship of the International Retinal Imaging Society. In 2022, she became a Laureate of the Future Vision Foundation. In 2025 she and Cynthia Owsley received the Proctor Medal from the Association of Research in Vision and Ophthalmology. She will be the 2025 Retina Research Foundation recipient and Schepens Lecturer for the 59th Annual Meeting of The Retina Society.

She is currently Professor Emerita, part time, at the University of Alabama at Birmingham Heersink School of Medicine, Department of Ophthalmology and Visual Sciences, where she was full-time faculty for 34 years. She trained at Brown University, University of Wisconsin- Madison and University of Rochester (Paul Coleman), Boston University (James Hinds), and University of Washington (Anita Hendrickson).

Future Vision Foundation



James P Dunn, MD

Professor, Sidney Kimmel Medical College at Thomas Jefferson University
Co-director of the Uveitis Unit in the Retina Division at Wills Eye Hospital

Contact Information

JPDunn@willseye.org

Wills Eye Hospital
Thomas Jefferson University

References

- Fine HF, Chang MA, Dunn JP Jr. Bilateral cryptococcal choroiditis. Arch Ophthalmol. 2004 Nov;122(11):1726-7. doi: 10.1001/archopht.122.11.1726. PMID: 15534144.

- Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group; Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May;132(5):527-537. doi: 10.1016/j.ophtha.2024.11.021. Epub 2024 Nov 28. PMID: 39612949; PMCID: PMC12018142.

- Chang M, Dunn JP. Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev Med Devices. 2005 Jul;2(4):421-7. doi: 10.1586/17434440.2.4.421. PMID: 16293081.

Narrative Biography

James Dunn, M.D. is Professor of Ophthalmology at Sidney Kimmel Medical College and Co-Director of the Uveitis Unit at Wills Eye Hospital. A graduate of Amherst College and New Jersey Medical School, he completed residency at NYU-Bellevue and fellowships at UCLA's Jules Stein Eye Institute and UCSF's Francis Proctor Foundation. He served on the faculty of the Wilmer Eye Institute at Johns Hopkins from 1991–2013 before joining Wills Eye Hospital in 2014.

For more than 35 years, Dr. Dunn has been a leader in the diagnosis and treatment of ocular infectious and inflammatory diseases, particularly HIV-related eye disease and CMV retinitis. As site Principal Investigator for landmark multicenter studies—including the Foscarnet Ganciclovir CMV Retinitis Trial, the Longitudinal Studies of Ocular Complications of AIDS, and the CMV Retinitis Viral Resistance Study—he helped define the clinical course and treatment of CMV retinitis both before and after the advent of antiretroviral therapy.

Dr. Dunn has advanced the role of imaging technologies such as OCT, OCT angiography, fluorescein angiography, and wide-field imaging in uveitis diagnosis and management. He has also contributed extensively to research on immunosuppressive drug therapy and regional corticosteroid delivery, including the ganciclovir, fluocinolone acetonide, and dexamethasone implants. He was a leading recruiter for the NEI-sponsored Multicenter Uveitis Steroid Trial and now serves as site investigator for the ongoing POINT Study.

Through clinical innovation, research, and teaching, Dr. Dunn has expanded diagnostic and therapeutic options for patients with complex ocular inflammatory diseases, helping to preserve vision worldwide.

Contact Information

dferrara@topcon.com

TopCon

References

- Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, Henry EC, Ferrara D. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 2018 Mar;125(3):369-390. doi: 10.1016/j.ophtha.2017.08.038. Epub 2017 Oct 27. PMID: 29110945.
- Ferrara D. Image artifacts in optical coherence tomography angiography. Clin Exp Ophthalmol. 2016 Jul;44(5):367-8. doi: 10.1111/ceo.12781. PMID: 27381573.
- Moreira-Neto CA, Moult EM, Fujimoto JG, Waheed NK, Ferrara D. Choriocapillaris Loss in Advanced Age-Related Macular Degeneration. J Ophthalmol. 2018 Jan 30;2018:8125267. doi: 10.1155/2018/8125267. PMID: 29651346; PMCID: PMC5831971.

FUTURE VISION FORUM

Daniela Ferrara, MD, MS, PhD, FASRS

Chief Medical Officer at Topcon Healthcare
Assistant Professor of Ophthalmology at Tufts University

Narrative Biography

Daniela Ferrara received her medical degree suma cum laude from Federal University of Rio de Janeiro, Brazil, one of the most prestigious universities in South America. During medical school, she joined a research group from the Biophysics Institute and conducted laboratory research projects on macromolecular metabolism. She completed a surgical internship and ophthalmology residency at the same University, followed by a Master's Degree in Ophthalmology. Dr. Ferrara completed her training at University of Sao Paulo, Brazil, achieving a PhD degree in Ophthalmology & Visual Sciences. Dr. Ferrara moved to the United States in 2006 to complete a research fellowship in Medical Retina at the Manhattan Eye, Ear & Throat Hospital affiliated to New York University, and since then she has been working on multimodal imaging analysis for clinical trials on retinal diseases. Dr. Ferrara's training and career are shaped to bring together basic research and clinical challenges.

Dr. Ferrara's major research interests include imaging of the posterior segment of the eye, and multimodal imaging analysis on pathological conditions of the vitreous, retina and choroid. As Assistant Professor of Ophthalmology at Tufts University School of Medicine, Dr. Ferrara is currently involved with the Optical Coherence Tomography Team at the New England Eye Center, a multidisciplinary group that promotes the scientific contribution on a clinical setting between retina specialists and the Massachusetts Institute of Technology..

Future Vision Foundation

Contact Information

Jthanda@jhmi.edu

Johns Hopkins University

References

- Miles D, Sforza D, Cano M, Peterson C, Gabrielson K, Wong JW, Handa J, Rezaee M. A Feasibility Study of Preclinical Ocular X-Ray FLASH Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025 Jun 28:S0360-3016(25)04521-3. doi: 10.1016/j.ijrobp.2025.06.3883. Epub ahead of print. PMID: 40588067; PMCID: PMC12314887.

- Toomey CB, Pflugmacher S, Park K, Pihl J, Weiser Novak S, Rodriguez J, Jalali M, Jung J, Mozafari M, Omran SP, Pormir CK, Hauer J, Painter C, Walker E, Huang AS, Boassa D, Handa JT, Aastrup T, Gordts PLSM, Esko JD. Bruch's membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration. Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2500727122. doi: 10.1073/pnas.2500727122. Epub 2025 Jun 13. PMID: 40512794; PMCID: PMC12184332.

- Miller JML, Thompson BR, Handa JT, Luthert P, Chakravarthy U, Csaky KG, Bird A, Young BK, Iyengar SK, Baek J, Zouache MA, Richards BT, Hageman GS, Rodrigues G, Bharti K, Flannery JG, Gorin MB, Bowes Rickman C. Dissecting the biological complexity of age-related macular degeneration: Is it one disease, multiple separate diseases, or a spectrum? Exp Eye Res. 2025 May;254:110304. doi: 10.1016/j.exer.2025.110304. Epub 2025 Feb 19. PMID: 39983974; PMCID: PMC12066171.

FUTURE VISION FORUM

James Handa, MD

Chief of Retina Division, Robert Bond Welch, MD
Professor of Opthalmology at Wilmer Eye Institute

Narrative Biography

James T. Handa, MD is the Robert Bond Welch Professor and Chief of the Retina Division at the Wilmer Eye Institute, Johns Hopkins University. He earned his BA in Biology from Brown University, taught as the Mailliard Teaching Fellow at the Taft School, and completed his MD at the University of Pennsylvania, where he was inducted into Alpha Omega Alpha. He trained in Ophthalmology at Wills Eye Hospital, serving as co-Chief Resident, followed by a vitreoretinal surgery fellowship at Duke Eye Center under pioneers including Robert Machemer, MD, and a second fellowship in intraocular oncology at USC.

Dr. Handa's research has centered on age-related macular degeneration (AMD), with a major focus on how cigarette smoking—AMD's strongest environmental risk factor—induces oxidative stress, mitochondrial injury, and Bruch's membrane alterations that drive disease progression. His laboratory has made fundamental contributions to understanding drusen biogenesis, mitochondrial dysfunction, and epithelial mesenchymal transition in retinal pigment epithelial cells.

Clinically, Dr. Handa is a leading vitreoretinal surgeon managing complex retinal disorders, including diabetic tractional detachments, retinopathy of prematurity, and intraocular malignancies. He was the implanting surgeon for the Argus II retinal prosthesis at Wilmer, contributing to its FDA approval.

Internationally recognized for both clinical and research excellence, Dr. Handa has served on the NEI AMD Pathobiology Group, received the Macula Society's Richard Green Award, and contributes to advisory boards for the Foundation Fighting Blindness and the Ryan Initiative for Macular Research. A dedicated mentor, he leads Wilmer's K12 Clinical Scientist Program, established the Wilmer Grant Review Committee, and directs retina resident and fellow education, cementing his impact on the next generation of clinician-scientists.

Future Vision Foundation

Contact Information

Jhopkins@aurabiosciences.com

Aura Biosciences

References

- Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11. PMID: 22330964.

- Hopkins J, Walsh A, Chakravarthy U. Fundus autofluorescence in age-related macular degeneration: an epiphenomenon? Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2269-71. doi: 10.1167/iovs.05-1482. PMID: 16723433.

- Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020 Nov;34(11):1966-1972. doi: 10.1038/s41433-020-0895-z. Epub 2020 Jun 15. PMID: 32541890; PMCID: PMC7784857.

FUTURE VISION FORUM

Jill Hopkins, MD, FRCSC

Chief Medical Officer
President of Research & Development

Narrative Biography

Jill Hopkins, MD, FRCSC

Jill Hopkins is the Chief Medical Officer and President of Research & Development at Aura Biosciences, where she oversees the development of viral drug conjugates in ocular and urologic oncology.

Before joining Aura, Jill served as Senior Vice President, Global Head of Ophthalmology and Exploratory Development at Novartis, and Chief Executive Officer of Gyroscope Therapeutics, a Novartis company. She was responsible for the global ophthalmic pipeline and portfolio of medicines, gene therapy, devices and digital solutions to impact eye disease and reduce visual impairment globally. Previously, Dr. Hopkins spent over a decade at Roche-Genentech in roles of increasing responsibility, most recently as Global Head Ophthalmology Personalized Health Care. Before Roche-Genentech, she spent over 20 years in clinical retinal research and academic practice at the University of Toronto, University of Southern California, and Retina-Vitreous Associates Medical Group.

Jill brings over 30 years of cross-sector experience in ophthalmology, spanning clinical care, academia, education, industry, advocacy, and innovation. Dr. Hopkins received her M.D. from McMaster University and completed her Ophthalmology residency at the University of Toronto. She has completed fellowships in Retinal Disease from Moorfields Eye Hospital in London UK and in Visual Electrophysiology from the Universities of Toronto and Ottawa. Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.

Future Vision Foundation

Contact Information

Suber.Huang@gmail.com

Future Vision Foundation/
Retina Center of Ohio

References

- Liu H, Huang SS, Lingam G, Kai D, Su X, Liu Z. Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases. Stem Cell Res Ther. 2024 Oct 31;15(1):390. doi: 10.1186/s13287-024-04007-5. PMID: 39482729; PMCID: PMC11526680.

- Ting DSW, Humayun MS, Huang SS; Future Vision Forum Faculty. Gaps and future of human-centered artificial intelligence in ophthalmology: Future Vision Forum consensus statement. Curr Opin Ophthalmol. 2023 Sep 1;34(5):431-436. doi: 10.1097/ICU.0000000000000984. Epub 2023 Jul 17. PMID: 37459295.

- Raman R, Rao C, Ruamviboonsuk P, Huang S, Sharma T. Single-use versus reuse of instruments in ophthalmic surgery. Eye (Lond). 2023 Oct;37(14):2839-2840. doi: 10.1038/s41433-023-02431-0. Epub 2023 Feb 8. PMID: 36754985; PMCID: PMC10517153.

FUTURE VISION FORUM

Suber Huang, MD, MBA

President/CEO Future Vision Foundation
President/CEO Retina Center of Ohio
Voluntary Assistant Professor, Bascom Palmer Eye Institute, University of Miami
Founding Editor in Chief, ASRS Retina Image Bank and Retina Atlas
Former President, American Society of Retina Specialists

Narrative Biography

Suber S. Huang, MD, MBA, FASRS is CEO of the Retina Center of Ohio, Voluntary Assistant Clinical Professor of Ophthalmology at Bascom Palmer Eye Institute, University of Miami, and Hong Leung Hong Leong Visiting Professor of Ophthalmology, National University of Singapore. He is Founder/CEO/Executive Producer of the Future Vision Foundation, whose mission celebrates breakthrough vision research through powerful documentaries of discovery, impact, and hope. He created the first-in-kind Future Vision Forum to bring visionary leaders in basic, translational, and clinical research together to seek new directions that accelerate discovery and innovation in vision research. He is a Director and Vice-Chair of the Science committee of the Foundation Fighting Blindness, on the Boards of Retina Global, Cleveland Sight Center, and founder of Cell Sight Therapeutics and SH Creative Arts, LLC.

He received his undergraduate degree at Johns Hopkins University, medical degree from the Albert Einstein College of Medicine, ophthalmology residency at the Wilmer Eye Institute/Johns Hopkins University and a fellowship in Vitreoretinal Diseases and Surgery from Bascom Palmer Eye Institute/University of Miami. He has graduate training at the Harvard University, Wharton School of Business/University of Pennsylvania, and received his Executive MBA from the Weatherhead School of Management/CWRU.

Dr. Huang was formerly President of the American Society of Retina Specialists, Chair of the Foundation of the ASRS, AAO Associate Secretariat of Federal Affairs, and Chair of the Research, Regulatory, and External Scientific Affairs Committee. From 1993-2014, Dr. Huang's leadership positions in the Case Western Reserve University (CWRU) Department of Ophthalmology and Visual Sciences include: Philip and Elizabeth Searle – Suber Huang MD Professor and Vice-Chair, Residency Program Director, and Director, Center for Retina and Macular Disease. He founded the Retina Diseases Image Analysis Reading Center and was Director of the Visual Sciences Research Center.

Dr. Huang has participated in numerous clinical trials as PI and as Director of the Retina Disease Image Analysis Reading Center at CWRU. He has published widely, given nearly 400 lectures, and has served as Program Chair for retina surgery for the APAO and AAO Retina sub-specialty day. He is/was DMC Chair for the Argus II retina and Orion cortical vision implant programs, ongoing gene therapy trials, stem cell transplant trials in atrophic AMD, and for the world's largest trial of triple therapy for onchocerciasis and lymphatic filariasis. He has active research interests in surgical innovation, gene- and cell-based therapy, the immunoregulatory properties of stem cells, and was Chair, National Eye Health Education Program, NEI/NIH.

Dr. Huang founded the ASRS Retina Image Bank, now the world's largest and most comprehensive open-access multimedia database of "all things retina". With over 40,000 images contributed, this site links expertise around the world. In 2023, the Image Bank exceeded three million cumulative page-views and has been used in 194 countries representing 99.2% of the world's population. He is the Founding Editor-in-Chief of the online ASRS Retina Atlas which launched in 2021 and aspires to be the world's most comprehensive, up-to-date, and continuously iteratively resource for retina knowledge. He is a founding officer of Retina Global an international organization focused on providing sustainable solutions to retinal disease management around the world. Dr. Huang is the AAO representative to the United States Pharmacopeia. He is a Director, Life Trustee, and bioscience advisor to the Anderson Scholars program at the University School.

Dr. Huang is an inductee to the Retina Hall of Fame, has received the "Top Doctors", "Best Doctors in America" awards each year since 2003, the AAO Secretariat (2), Senior Honor Awards, ASRS Presidential, Senior Achievement and Honor Awards. He received the APAO Jose Rizal International Medal, APVRS International Award, Chinese Vitreo-Retinal Society Senior Honor Award, Vitreo-Retinal Society of India President's Award, the Johns Hopkins University School of Medicine/Wilmer Eye Institute Distinguished Alumnus Award, CWRU Department of Ophthalmology Attending of the Year and cherishes the CWRU Humanism in Medicine award given to the faculty member who most demonstrates compassion and professionalism in the care of patients and their families. Other awards include the Rainbow Babies and Children's Hospital Pediatric Innovation, OPS J. Donald M. Gass MD award, International Congress of Ophthalmic Photographers, the National Diversity Council Leadership Excellence Award, and the Cleveland Sight Center Person of the Year. Dr. Huang has produced 12 documentary films including Seven Years of Darkness (best short documentary, National Short Film Festival) and Candle in the Distance (Rhett Buckler award, ASRS Film Fest). In 2023, received the Fight for Sight Vision Research Advocate Award and the ASRS Packo award, given for extraordinary service to the Society and the profession. In 2024, he was lauded as a Crain's Notable Leader in Healthcare.

Future Vision Foundation

Contact Information

szk7001@med.cornell.edu

Cornell University

References

- Lin M, Shah J, Alonso L, Kiss S, Kovacs K. Retinal Imaging Findings in Patients with Maturity-Onset Diabetes of the Young. Ophthalmol Sci. 2025 Feb 11;5(3):100737. doi: 10.1016/j.xops.2025.100737. PMID: 40130266; PMCID: PMC11930792.

- Poulsen K, Hanna K, Nieves J, Nguyen N, Sharma P, Grishanin R, Corbau R, Kiss S. Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes. Mol Ther Methods Clin Dev. 2025 Feb 10;33(1):101430. doi: 10.1016/j.omtm.2025.101430. PMID: 40092639; PMCID: PMC11910100.

- Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK. Review of gene therapies for age-related macular degeneration. Eye (Lond). 2022 Feb;36(2):303-311. doi: 10.1038/s41433-021-01842-1. Epub 2022 Jan 11. PMID: 35017696; PMCID: PMC8807824.

FUTURE VISION FORUM

Szilard Kiss, MD

Bob and Dolores Hope- Robert M. Ellsworth, MD Distinguished Professor of Ophthalmology

Narrative Biography

I received an undergraduate degree with honors from Columbia College, medical school training at Columbia University Vagelos College of Physicians & Surgeons and completed an ophthalmology residency and surgical vitreoretinal fellowship at Harvard Medical School and the Massachusetts Eye & Ear Infirmary, where I was selected by the faculty to serve as the Chief Retina Fellow. My research career started as an undergraduate at Columbia College where, in conjunction with the National Aeronautics and Space Administration (NASA) and the Department of Defense, I evaluated the implications of microgravity on early developmental patterning with scientific experiments launched on the space shuttle Discovery (STS-70) and the space shuttle Columbia (STS-78). I am currently the Associate Dean of Clinical Compliance, Chair of the General Faculty Council, Vice-Chair of Research, Vice-Chair of Compliance, Chief of the Retina Service, Director of Teleophthalmology, and Associate Professor of Ophthalmology at Weill Cornell Medical College. Currently, my clinical and translational research efforts focus on four broad areas: ocular gene and cellular therapy, novel therapeutic targets for ocular neovascularization, complex vitreoretinal surgical techniques, and retinal imaging. I have participated as a principal investigator in over three-dozen prospective clinical trials and laboratory investigations. I have authored over 270 scientific publications, given nearly 250 invited lectureships worldwide, and serve on the Editorial Board and as a scientific reviewer to a number of major journals. In addition to my scientific efforts, I have garnered a reputation as a world renowned medical and surgical vitreoretinal specialist; my clinical practice draws patients from all regions of the world. For my academic and clinical work, I have won numerous academic and scientific awards including the Schepens Eye Research Institute Joint Clinical Research Center Pilot Project Grant, the Heed Ophthalmic Foundation Fellowship Award, the Ronald G. Michels Foundation Fellowship Award, the Paul Kayser International Fellowship Award, American Society of Retina Specialists Rhett Buckler Award, and the Research to Prevent Blindness Physician-Scientist Award. For my contributions to ophthalmology, I have received the Honor and Senior Honor Awards from the American Society of Retina Specialists and the Honor Award from the American Academy of Ophthalmology. I was also among a select group of retina specialists worldwide (and the youngest) to be elected by his peers as a Charter Member of the Retina Hall of Fame. I have also been named to several regional, national and international Top Doctors lists, including The Ophthalmologist Power List Top 40 Under 40 Ophthalmologist Worldwide, OSN Retina 150 Leading Innovators in Surgical and Medical Retina, Castle Connolly's Top Reginal Doctors, and New York Super Doctors.

Future Vision Foundation

Contact Information

jennylim@uic.edu

University of Illinois

References

- Ipp E, Liljenquist D, Bode B, Shah VN, Silverstein S, Regillo CD, Lim JI, Sadda S, Domalpally A, Gray G, Bhaskaranand M, Ramachandra C, Solanki K; EyeArt Study Group. Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy. JAMA Netw Open. 2021 Nov 1;4(11):e2134254. doi: 10.1001/jamanetworkopen.2021.34254. Erratum in: JAMA Netw Open. 2021 Dec 1;4(12):e2144317. doi: 10.1001/jamanetworkopen.2021.44317. PMID: 34779843; PMCID: PMC8593763.
- Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016 May 6;16:52. doi: 10.1186/s12886-016-0225-1. Erratum in: BMC Ophthalmol. 2016 Jul 29;16(1):129. doi: 10.1186/s12886-016-0259-4. PMID: 27154461; PMCID: PMC4858839.
- Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Erratum to: Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016 Jul 29;16(1):129. doi: 10.1186/s12886-016-0259-4. Erratum for: BMC Ophthalmol. 2016 May 06;16:52. doi: 10.1186/s12886-016-0225-1. PMID: 27473341; PMCID: PMC4965894.

FUTURE VISION FORUM

Jennifer Lim, MD

UIC Distinguished Professor of Ophthalmology; Marion H. Schenk Esq Chair in Ophthalmology for Research of the Aging Eye, Director Retina Service
Vice Chair for Diversity and Inclusion

Narrative Biography

My research interests focus upon clinical trials, translational research, artificial intelligence (AI) and imaging. I have served as PI on over 70 multicenter clinical trials, served on Data Monitoring Committees and Executive Committees for clinical trials. I collaborate with basic scientists on angiogenesis research, AI and imaging research. I utilize spectral domain optical coherence tomography (SD-OCT) and OCT angiography (OCTA) imaging of the retina to study how structural changes affect visual acuity and therapeutic outcomes. A recent focus is OCTA artery-vein differential analysis for which I have an R01 grant. Ongoing and recently completed projects that I would like to highlight include:

1. NIH-NEI R01EY030842 Differential artery-vein analysis in OCT angiography for objective classification of diabetic retinopathy 2/1/20-1/31/25. Role: Co-PI with Xincheng Yao PhD.

2. NIH-NEI R01EY023522 Functional imaging of retinal photoreceptors. PI Xincheng Yao PhD. 04/01/2021-03/31/2026. Role: Co-I.

3. NIH-NEI R15EY035804-01 Distributed approaches to train machine learning models in diabetic retinopathy. PI Minhaj N. Alam PhD. 03/01/24-02/28/27. Role: Co-I 4. Investigator Initiated Study (IIS). Assessment NeurovAscuLar dYSfunction Early Retinopathy (ANALYSER) Study. Role: PI.

Future Vision Foundation

Contact Information

Keith.Luhrs@bausch.com

Bausch & Lomb

References

- Hallak JA, Abbasi A, Goldberg RA, Modi Y, Zhao C, Jing Y, Chen N, Mercer D, Sahu S, Alobaidi A, López FJ, Luhrs K, Waring JF, den Hollander AI, Smaoui N. Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease. JAMA Ophthalmol. 2024 Aug 1;142(8):750-758. doi: 10.1001/jamaophthalmol.2024.2376. PMID: 38990568; PMCID: PMC11240228.

- Parseghian MH, Luhrs KA. Beyond the walls of the nucleus: the role of histones in cellular signaling and innate immunity. Biochem Cell Biol. 2006 Aug;84(4):589-604. doi: 10.1139/006-082. PMID: 16936831.

- Walsh CM, Luhrs KA, Arechiga AF. The "fuzzy logic" of the death-inducing signaling complex in lymphocytes. J Clin Immunol. 2003 Sep;23(5):333-53. doi: 10.1023/a:1025313415487. PMID: 14601642.

FUTURE VISION FORUM

Keith Luhrs, PhD

VIce President of Pharma Research & External Scientific Innovations

Narrative Biography

Dr. Luhrs is the Vice President of Pharma Research & External Scientific Innovation of Bausch + Lomb based at their Irvine, California West Coast Hub. In this role, he leads an integrated internal research and external science evaluation and collaboration group dedicated to helping our patients by building an innovative pipeline for indications spanning the eye. After an academic career in immunology and a start in oncology biotech, Dr. Luhrs has been focused on ophthalmology drug discovery and development for more than 15 years—and never looked back. Prior to Bausch + Lomb, he held various roles at Allergan and AbbVie prior to leading their retina and ocular surface discovery research teams. Dr. Luhrs received his B.S. in Biological Sciences from Penn State University and a Ph.D. from the University of California—Irvine.

Future Vision Foundation

Contact Information

Prithvi9@stanford.edu

Stanford University

References

- Lee EB, Al-Moujahed A, Yu MD, Ta CN, Lin JH, Mruthyunjaya P. Corneally displaced conjunctival Melanoma: Rare presentations of recurrent melanoma. Am J Ophthalmol Case Rep. 2025 Jul 15;39:102387. doi: 10.1016/j.ajoc.2025.102387. PMID: 40741594; PMCID: PMC12309019.
- Murty T, Wai KM, Rahimy E, Mruthyunjaya P. Low Occurrence of Ocular Adverse Events after CAR-T Cell Therapy. Ocul Oncol Pathol. 2025 Jul;11(2):104-108. doi: 10.1159/000543055. Epub 2025 Jan 24. PMID: 40726603; PMCID: PMC12296209.
- Amarikwa L, Chandraparnik P, Wai KM, Rahimy E, Kinde B, Koo E, Ludwig C, Dosiou C, Mruthyunjaya P, Kossler AL. Risk of developing thyroid eye disease in patients with thyroid dysfunction that received a COVID-19 vaccination. Can J Ophthalmol. 2025 Jul 30:S0008-4182(25)00320-5. doi: 10.1016/j.jcjo.2025.06.017. Epub ahead of print. PMID: 40684801.

FUTURE VISION FORUM

Prithvi Mruthyunjaya, MD, MHS

Alan Adler Professor of Ophthalmology and Radiation Oncology at Stanford University
Member of the Vitreoretinal Surgery Service
Director of Ocular Oncology at the Byers Eye Institute

Narrative Biography

Prithvi Mruthyunjaya MD, MHS is the inaugural Alan Adler Professor of Ophthalmology and Radiation Oncology at Stanford University, member of the Vitreoretinal Surgery Service and the Director of Ocular Oncology at the Byers Eye Institute since 2016. Dr. Mruthyunjaya is a clinician-educator whose clinical interest lies in a multi-disciplinary, vitreoretinal approach to ocular tumors, and complex vitreoretinal disorders. He manages both adult and pediatric ocular cancers with a focus on novel therapeutics, intraocular biopsy, and vision-saving strategies to reduce treatment toxicity. As Director of the Vitreoretinal Surgery Fellowship at Stanford, he has created a coveted, academic-focused retina training program. To date, he has trained over 50 retina and ocular oncology fellows who have distinguished themselves by their clinical excellence, research, and recognition by leading retina organizations. As a NIH funded investigator and recipient of the Retina Research Foundation/Macula Society research awards, he has coauthored over 200 peer-reviewed publications and textbook chapters in leading journals including Ophthalmology, Journal of Clinical Oncology, Molecular Cancer, and Cell. Collaboration remains a hallmark of his career having been an inaugural member of the CONNECT network, founding member of the Ocular Oncology Study Consortium, executive committee member for the Collaborative Ocular Oncology Group and on the clinical trial protocol committee for the DRCR Retina Network. He has been honored with the Heed, Heed-Knapp, and Ronald G. Michels Foundation fellowships, American Society of Retina Specialists (ASRS) Presidential Honor Award, American Academy of Ophthalmology Senior Achievement and Secretariat Awards. He has been inducted into Alpha Omega Alpha honor society and the Global Retinal Hall of Fame. He is an elected member of the prestigious Retina Society, Macula Society, and the Club Jules Gonin. He was recognized by his students with educator of the year awards at both Duke and Stanford Universities and by his global peers with the 2023 American Society of Retina Specialists Crystal Apple award, their highest teaching honor.

Future Vision Foundation

Contact Information

Marlana.Orloff@jefferson.edu

Thomas Jefferson University

References

- Najjar YG, Orloff M, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. Ther Adv Med Oncol. 2025 Jun 14;17:17588359251342039. doi: 10.1177/17588359251342039. PMID: 40535733; PMCID: PMC12174741.

- Terai M, Seedor R, Ashraf U, Hubbard G, Koshkin S, Orloff M, Sato T. Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma. J Clin Med. 2025 Apr 18;14(8):2815. doi: 10.3390/jcm14082815. PMID: 40283643; PMCID: PMC12028195.

- Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. Ann Surg Oncol. 2025 Jul;32(7):4976-4988. doi: 10.1245/s10434-025-17231-x. Epub 2025 Apr 7. PMID: 40192993; PMCID: PMC12130151.

FUTURE VISION FORUM

Marlana Orloff- Dacey, MD

Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma

Narrative Biography

Dr. Marlana Orloff is an associate professor of Medical Oncology, Alexander & Johnston Family Endowed Clinical Director of Uveal Melanoma, and Co-Director Melanoma Research Institute of Excellence at Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center in Philadelphia, PA.

Her clinical focus is on primary and advanced melanomas, specifically rare melanomas including mucosal, conjunctival, and uveal melanoma. Her research is focused on the development of novel therapies for these rare melanoma subtypes.

Future Vision Foundation

Contact Information

Hpenny@aurabiosciences.com

Aura Biosciences

References

- Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023 Oct 10;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011. PMID: 37820582.
- de Paiva CS, St Leger AJ, Caspi RR. Mucosal immunology of the ocular surface. Mucosal Immunol. 2022 Jun;15(6):1143-1157. doi: 10.1038/s41385-022-00551-6. Epub 2022 Aug 24. PMID: 36002743; PMCID: PMC9400566.
- Wu M, Fletcher EL, Chinnery HR, Downie LE, Mueller SN. Redefining our vision: an updated guide to the ocular immune system. Nat Rev Immunol. 2024 Dec;24(12):896-911. doi: 10.1038/s41577-024-01064-y. Epub 2024 Aug 30. PMID: 39215057.

FUTURE VISION FORUM

Xianne Penny, PhD, NREMT

Senior Director, Clinical Development Scientist(Immuno-Oncology)

Narrative Biography

Xianne (“see-anne”) Penny is a classically trained immuno-oncologist (BSc Brown, PhD Stanford, NREMT Denver Paramedic School). Xianne has over 2 decades of experience in research and clinical development in the field of immuno-oncology across a broad spectrum of cancer types, such as liver, colorectal, pancreatic, prostate, glioblastoma, multiple myeloma, acute lymphoblastic leukemia, myelodysplastic syndrome, as well as in autoimmune/inflammatory conditions such as Rheumatoid Arthritis and Alzheimer’s disease. After a 5 ½ year postdoctoral fellowship at the Singapore Immunology network, Xianne trained in big pharma at Amgen, Thousand Oaks, for 5 ½ years as a clinical immunologist, before transitioning to Clinical Development in the small biotech sphere at Halia Therapeutics. As medical monitor there, Xianne led clinical trials in dental inflammatory pain and myelodysplastic syndrome. She currently serves at Aura Biosciences as Senior Director, Clinical Development, executing clinical trials and helming biomarker strategy in bladder cancer and choroidal melanoma studies. From academia to industry, Xianne is beyond thankful for the incredible privilege to perform first-in-class, purpose-driven, life-changing work, as both a witness and a driver of the IO revolution that has transformed the field of oncologic medicine over the years.

Future Vision Foundation

Contact Information

Stephen.poor@apellis.com

Apellis

References

- Dunbar HMP, Crabb DP, Behning C, Binns AM, Abdirahman A, Terheyden JH, Poor S, Finger RP, Leal S, Tufail A, Holz FG, Schmid M, Luhmann UFO; MACUSTAR Consortium. Heterogeneous Visual Function Deficits in Intermediate Age-Related Macular Degeneration: A MACUSTAR Report. Ophthalmol Sci. 2025 Jan 13;5(4):100708. doi: 10.1016/j.xops.2025.100708. PMID: 40212936; PMCID: PMC11985047.

- Emilsson V, Gudmundsson EF, Jonmundsson T, Jonsson BG, Twarog M, Gudmundsdottir V, Li Z, Finkel N, Poor S, Liu X, Esterberg R, Zhang Y, Jose S, Huang CL, Liao SM, Loureiro J, Zhang Q, Grosskreutz CL, Nguyen AA, Huang Q, Leehy B, Pitts R, Aspelund T, Lamb JR, Jonasson F, Launer LJ, Cotch MF, Jennings LL, Gudnason V, Walshe TE. A proteogenomic signature of age-related macular degeneration in blood. Nat Commun. 2022 Jun 13;13(1):3401. doi: 10.1038/s41467-022-31085-x. PMID: 35697682; PMCID: PMC9192739.

- Ghosh JG, Nguyen AA, Bigelow CE, Poor S, Qiu Y, Rangaswamy N, Ornberg R, Jackson B, Mak H, Ezell T, Kenanova V, de la Cruz E, Carrion A, Etemad-Gilbertson B, Caro RG, Zhu K, George V, Bai J, Sharma-Nahar R, Shen S, Wang Y, Subramanian KK, Fassbender E, Maker M, Hanks S, Vrouvlianis J, Leehy B, Long D, Prentiss M, Kansara V, Jaffee B, Dryja TP, Roguska M. Long-acting protein drugs for the treatment of ocular diseases. Nat Commun. 2017 Mar 23;8:14837. doi: 10.1038/ncomms14837. PMID: 28332616; PMCID: PMC5376645.

FUTURE VISION FORUM

Stephen Poor, MMBBS MRCOphth

Head of Translational Medicine

Narrative Biography

Physician-scientist (UK-trained Ophthalmologist) with over 20 years of Biotech drug discovery and drug development. Current role is Head of Translational Medicine at Apellis with broad cross-organizational responsibilities, covering many indications (Ophthalmology, Neurology, Dermatology, Nephrology and hematology). Mission includes clinical trial leadership, developing technology, BD&L support, strategy, clinical end point development and optimizing clinical trial execution.

My personal mission is to develop Science and Technology to deliver life changing/enhancing/preserving therapies as part of highly effective, growth oriented, self-critical, supportive, fun-loving teams. My values are a commitment to joy, determination, courage, compassion, growth and mentorship.

Previous roles include Head of Retinal Pharmacology, Director of External Innovation, Global Program Clinical Head @ Novartis. Extensive experience with Angiogenesis, Complement, Gene Therapy, Long-Acting programs and Pharma cross-organizational drug development efforts/engagement/alignment.

Future Vision Foundation

SriniVas Sadda, MD

Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute
Professor of Ophthalmology at the University of California –Los Angeles (UCLA) Geffen School of Medicine

Contact Information

ssadda@mednet.ucla.edu

University of California, Los Angeles

References

- Invernizzi A, Agarwal A, Gangaputra S, Airaldi M, Carreno E, Munk MR, Pichi F, Shantha J, Agrawal R, Sadda S, Jampol LM, Smith JR, Jabs DA, Chee SP, Sarraf D, Gupta V; Multimodal Imaging in Uveitis (MUV) Task Force. Minimum Imaging Sets for Diagnosis, Activity Assessment and Complications in Non-Infectious Posterior Uveitis: MUV Report 9. Am J Ophthalmol. 2025 Aug 1:S0002-9394(25)00391-5. doi: 10.1016/j.ajo.2025.07.029. Epub ahead of print. PMID: 40754260.

- Lan T, Huang C, Tao M, Xu X, Zhou J, Lin Y, Sadda S, Luo Y. The feasibility of Ultra-widefield SS-OCTA to guide laser photocoagulation in retinal vascular diseases. Retina. 2025 Jun 24. doi: 10.1097/IAE.0000000000004593. Epub ahead of print. PMID: 40720704.

- Voichanski S, Bousquet E, Abraham N, Mafi M, Santina A, Fossataro C, Fossataro F, He Y, Sadda S, Sarraf D. En Face OCT and the Phenotype Characterization of Drusen. Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):52. doi: 10.1167/iovs.66.9.52. PMID: 40679333; PMCID: PMC12302042.

Narrative Biography

SriniVas R. Sadda, MD, is the Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine. He is the immediate past President of the Doheny Eye Institute, the Macula Society, and the Association for Research in Vision and Ophthalmology (ARVO). He has served as ARVO representative to the AAO council for the past three years. He received his MD from Johns Hopkins University, where he also completed ophthalmology residency and neuro-ophthalmology and medical retina fellowships (Wilmer Eye Institute). Dr. Sadda's major research interests include retinal image analysis, advanced retinal imaging technologies, and clinical trial endpoint design. He was the Founding Director of the Doheny Image Reading Center. He has more than 825 peer-reviewed publications (h-index = 113; > 50,000 citations) and 20 book chapters, and has given over 600 presentations worldwide. Dr. Sadda is Editor-in-Chief of the 7th Edition of Ryan's Retina. He also serves as an Editor-in-Chief of Graefe's Archive for Clinical and Experimental Ophthalmology and is an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Ophthalmology Retina, Ophthalmology Science and Ophthalmology. Among Dr. Sadda's awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, an Achievement Award and a Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, the Macula Society's Young Investigator Award, American Society of Retina Specialists Young Investigator Award, Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award, The Macula Society's Paul Henkind Lecture and W. Richard Green Lecture, the Euretina Lecture, The Retina Society's Charles Schepens Lecture, and the Vitreoretinal Society of India Nataraja Pillai Oration. He served as President of the Macula Society from 2024 – 2025. Dr. Sadda's research has been continuously funded by the National Institutes of Health for several years, including two current R01 grants from the National Eye Institute. He has been named to the Best Doctors of America list for several consecutive years.

FUTURE VISION FORUM

Jose Alain Sahel, MD

Distinguished Professor and Chairman of the Department of Ophthalmology University of Pittsburgh Medical School, The Eye and Ear Foundation Endowed Chair,
Distinguished Professor and Chairman of the Department of Ophthalmology University of Pittsburgh Medical School, The Eye and Ear Foundation Endowed Chair
Director, UPMC Vision Institute
Exceptional Class Professor of Ophthalmology - Sorbonne Université
Director of the Institut Hospitalo-Universitaire FOReSIGHT
Adjunct Professor of Robotics and Bioengineering, Carnegie Mellon University, Pittsburgh
Adjunct Professor, Hebrew University of Jerusalem, Israel
Honorary Professor, Institute of Ophthalmology, University College London

Contact Information

sahelja@upmc.edu

University of Pittsburgh

References

- Sahel JA, Bennett J, Roska B. Depicting brighter possibilities for treating blindness. Sci Transl Med., 2019 May 29;11(494). pii: eaax2324.
- Sahel JA, Grieve K, Pagot C, Authié C, Mohand-Said S, Paques M, Audo I, Becker K, Chaumet-Riffaud AE, Azoulay L, Gutman E, Léveillard T, Zeitz C, Picaud S, Dalkara D, Marazova K. Assessing photoreceptor status in retinal dystrophies: from high resolution imaging to functional vision. Am J. Ophthalmol. 2021 : S0002-9394(21)00212-9
- Sahel JA, Boulanger-Scemama E, Pagot C, Arleo A, Galuppi F, Martel JN, Degli Esposti S, Delaux A, de Saint Aubert JB, de Montleau C, Gutman E, Audo I, Duebel J, Picaud S, Dalkara D, Blouin L, Taiel M, Roska B. Partial recovery of visual function in a blind patient after optogenetic therapy. Nature Medicine 2021 Jul;27(7):1223-1229.

Narrative Biography

Dr. José-Alain Sahel is a Distinguished Professor and Chairman of Ophthalmology at the University of Pittsburgh School of Medicine, and Emeritus Professor at Sorbonne University. He trained at Paris University, Strasbourg Louis Pasteur University, and Harvard. He founded two Vision Institutes in Paris and Pittsburgh and focuses on vision restoration and retinal diseases. He conducted over 80 clinical trials on retinal conditions, including first-in-human trials on retinal implants, gene therapy, neuroprotection and Optogenetics. He has published over 750 peer-reviewed articles, holds 90 patents, and co- founded companies for vision therapies. He collaborates with international organizations and institutions, advancing the diagnosis and treatment of rare eye diseases, improving the lives of patients worldwide. His memberships include the Académie des Sciences, the Leopoldina German Academy of Sciences, the Association of American Physicians, and the National Academy of Inventors. He received multiple awards including the Liggett Gund Award from Foundation Fighting Blindness and, in 2024, with Botond Roska, the Wolf Prize in Medicine.

Future Vision Foundation



Contact Information

Takami.Sato@jefferson.edu

Thomas Jefferson University Hospital

References

- Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 1;131(15):e70022. doi: 10.1002/cncr.70022. PMID: 40753466.

- Terai M, Seedor R, Ashraf U, Hubbard G, Koshkin S, Orloff M, Sato T. Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma. J Clin Med. 2025 Apr 18;14(8):2815. doi: 10.3390/jcm14082815. PMID: 40283643; PMCID: PMC12028195.

- Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, Khakoo S, Collins L, de la Cruz-Merino L, Eroglu Z, Ikeguchi AP, Nathan P, Hamid O, Butler MO, Stanhope S, Ranade K, Sato T. Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. Cell Rep Med. 2025 Apr 15;6(4):102076. doi: 10.1016/j.xcrm.2025.102076. PMID: 40239619; PMCID: PMC12047528.

FUTURE VISION FORUM

Takami Sato, MD, PhD

Director, Metastatic Uveal Melanoma, K. Hasumi, MD
Professor in Medical Oncology Professor

Narrative Biography

As director of the Metastatic Uveal Melanoma Program at Jefferson, Dr. Sato heads one of the few programs in the United States treating melanoma originating in the eye. Although uveal melanoma is the most common adult eye tumor, the disease is very rare, affecting only six or seven people per one million. This cancer commonly spreads to the liver, and patients who do not receive treatment live an average of six months. Dr. Sato has devoted his career to improving understanding of this disease and developing new treatments, particularly for patients who are not eligible for surgery.

Dr. Sato's studies focus on cancer immunotherapy, or the use of the immune system to fight cancer. His clinical trials involving a procedure called immunoembolization have shown promising results.

In immunoembolization, a chemical to stimulate patients' immune systems is administered to the hepatic artery that feeds the liver tumor and then the artery is blocked, cutting off oxygen to tumors and keeping the injected medicine in the tumor. In one trial, one-third of patients had tumor shrinkage, and another third experienced no tumor growth. Dr. Sato is building on these outcomes as he continues to examine methods of treating uveal melanoma and delaying its progression.

Future Vision Foundation



Contact Information

Rino.seedor@jefferson.edu

Thomas Jefferson University

References

- Orloff M, Seedor R, Sato T. Review of bi-specific therapies in uveal melanoma. Cancer Gene Ther. 2022 Dec;29(12):1814-1818. doi: 10.1038/s41417-022-00442-9. Epub 2022 Mar 2. PMID: 35236927.

- Terai M, Seedor R, Ashraf U, Hubbard G, Koshkin S, Orloff M, Sato T. Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma. J Clin Med. 2025 Apr 18;14(8):2815. doi: 10.3390/jcm14082815. PMID: 40283643; PMCID: PMC12028195.

- Seedor RS, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M, Sacco JJ, Smalley K, Selig SM. Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023. Pigment Cell Melanoma Res. 2025 Jan;38(1):e13205. doi: 10.1111/pcmr.13205. Epub 2024 Oct 9. PMID: 39385554; PMCID: PMC11967437.

FUTURE VISION FORUM

Rino Seedor, MD

Assistant Professor

Narrative Biography

Rino S. Seedor, MD Assistant Professor of Medical Oncology at Sidney Kimmel Comprehensive Cancer Center – Jefferson Health Dr. Rino Seedor is an Assistant Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center (Jefferson Health) in Philadelphia, PA. She completed her medical school and residency training at Jefferson and was briefly at Fox Chase Cancer Center before returning to Jefferson as faculty. Her clinical and research focus is on prevention and treatment of melanoma, both cutaneous and uveal. She is the principal investigator and co-investigator of several therapeutic clinical trials in melanoma at Jefferson, including an investigator-initiated trial of neoadjuvant tebentafusp in primary uveal melanoma. She works very closely with the ocular oncology team at Wills Eye Hospital and she is a member of the multidisciplinary team of medical oncologists, interventional radiologists, radiation oncologist and numerous other essential personnel at Jefferson that manages patients with uveal melanoma from all over the country.

Future Vision Foundation

Carol Shields, MD

Director, Ocular Oncology Services

Contact Information

Carolshields@gmail.com

Wills Eye Hospital

References

- Singh H, Kurian DE, Shields CL. Globe Volume Asymmetry After Intra-arterial Chemotherapy for Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2025 Jul-Aug;62(4):e46-e50. doi: 10.3928/01913913-20250520-01. Epub 2025 Jul 1. PMID: 40700305.
- Cohen SY, Lathiere T, Marechal V, Rodriguez F, Souied E, Shields CL. Unilateral Retinal Pigment Epithelium Dysgenesis (URPED): New Cases, Literature Review, and Considerations of the Similarities and Differences with Combined Hamartoma of the Retina and Retinal Pigment Epithelium (CHRRPE). Retin Cases Brief Rep. 2025 Jul 14. doi: 10.1097/ICB.0000000000001785. Epub ahead of print. PMID: 40690768.
- Card KR, Zaloga AR, Konstantinou EK, Shields CL. Clinical factors predictive of tumour cytogenetics and metastasis in 86 patients with choroidal nevus growth into melanoma (DIP and DOT study). Br J Ophthalmol. 2025 Jul 15:bjo-2024-325703. doi: 10.1136/bjo-2024-325703. Epub ahead of print. PMID: 40664489.

Narrative Biography

Dr. Carol Shields completed her residency in ophthalmology at Wills Eye Hospital in Philadelphia in 1987 and subsequently did fellowship training in ocular oncology, oculoplastic surgery, and ophthalmic pathology. She is currently Director of the Oncology Service, Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia. She has authored or coauthored 12 textbooks, 341 chapters in edited textbooks, over 2000 articles in major peer-reviewed journals, given over 1000 lectureships, and has received numerous professional awards. The 20 most prestigious achievements include:

- The Byron Kanaley Award (1979) given to the top student-athlete at the University of Notre Dame. She was the first woman to receive this award.
- The Donders Award (2003) given by the Netherlands Ophthalmological Society every 5 years to an ophthalmologist worldwide who has contributed extensively to the field of ophthalmology. She was the first woman to receive this award.
- Honorary Doctorate of Science Degree from the University of Notre Dame (2005) She was the first woman graduate of Notre Dame to receive this award.
- Honorary Doctorate of Science Degree from the Catholic University (2011).
- The American Academy of Ophthalmology Life Achievement Honor Award (2011) for significant contributions to the field of ophthalmology.
- The Moose Krause Award (2006) given to graduated student athlete from the University of Notre Dame who demonstrates leadership and accomplishments in the athletic, academic, and humanities fields. Most coveted athletic award given by the University and first woman to receive this award.
- Induction into the Academic All-American Hall of Fame (2011) for lifetime success in athleticism and career.
- The Retina Research Award of the Retina Society (2006) – for excellence in retina research.
- The Strittmater Award (2010) – given by the Philadelphia Medical Society to honor a physician of outstanding contributions.
- The Doyne Lecture (2015)– This is the oldest invited named lectureship in the United Kingdom, giving at the Oxford Congress.
- The J. Donald M. Gass Lecture of the Retina Society (2019)
- JAMA Ophthalmology Editorial Board – appointed 2017 to present
- President of the International Society of Ocular Oncology (2013-2015) – This is the largest international society of clinicians and basic scientists interested in ocular tumors. She was the first elected President of this society.
- President of the Macula Society (2020) – This is the leading society for retina and vitreous doctors in the world. She served as Treasurer (2017), Secretary (2018), Vice President (2019), and President (2020).
- Director, Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA (2017-present).
- Ophthalmology Power List - Nominated by peers as one of the top 100 leaders in the field of ophthalmology by the journal, The Ophthalmologist. She was listed "Top 100" power lists in 2014-2023. In 2020 and 2023, Dr. Carol Shields was listed at #1 in the Ophthalmology Power List.
- Icons in Opthalmology (2020) – an award given to the "Top 5 Ophthalmologists" worldwide and sponsored by Bausch and Lomb Inc, England
- America's Best Eye Doctors [July 21, 2021]- Nominated by Newsweek magazine with an overall rank #7 of all ophthalmologists and rank #1 of all female ophthalmologists
- The Theodore Roosevelt Award (January 11, 2023)- the highest honor the National Collegiate Athletic Association (NCAA) confers on an individual who earned a varsity letter for sports in college and who became a distinguished citizen of national reputation.
- World Eye-Con 21st Century Award [February 3, 2024] Nominated by the Asia Pacific Society of Ophthalmology and the Asia Pacific Journal of Ophthalmology (APJO). The first 24 world EYECONS who helped shaped the world of ophthalmology in the 21st century
- A wonderful family Dr. Carol Shields is a member of numerous ocular oncology, pathology, and retina societies and has delivered 74 named lectures in America and abroad. She has been active in the American Academy of Ophthalmology. She serves on the editorial/advisory board of 33 journals including JAMA Ophthalmology, Retina, Ophthalmic Plastic and Reconstructive Surgery, Asia Pacific Journal of Ophthalmology, Indian Journal of Ophthalmology, and International Journal of Clinical Oncology. Her Google Scholar H-index is 122 and her Scopus H-index is 93. She practices Ocular Oncology on a full-time basis with her associates on the Oncology Service at Wills Eye Hospital. Each year the Oncology Service manages approximately 500 patients with uveal melanoma, 120 patients with retinoblastoma, and numerous other intraocular, orbital, and adnexal tumors from the United States and abroad. She and her husband Jerry are the parents of 7 children, ranging in age from 22 to 34 years.



Contact Information

mandeep@jhmi.edu

Wilmer Eye Institute
Johns Hopkins University

References

- Singh MS, Park SS, Albini TA, Canto-Soler MV, Klassen H, MacLaren RE, Takahashi M, Nagiel A, Schwartz SD, Bharti K. Retinal stem cell transplantation: Balancing safety and potential. Prog Retin Eye Res. 2020 Mar;75:100779. doi: 10.1016/j.preteyeres.2019.100779. Epub 2019 Sep 5. PMID: 31494256; PMCID: PMC7056514.

- Cehajic-Kapetanovic J, Singh MS, Zrenner E, MacLaren RE. Bioengineering strategies for restoring vision. Nat Biomed Eng. 2023 Apr;7(4):387-404. doi: 10.1038/s41551-021-00836-4. Epub 2022 Jan 31. PMID: 35102278.

- Liu YV, Santiago CP, Sogunro A, Konar GJ, Hu MW, McNally MM, Lu YC, Flores-Bellver M, Aparicio-Domingo S, Li KV, Li ZL, Agakishiev D, Hadyniak SE, Hussey KA, Creamer TJ, Orzolek LD, Teng D, Canto-Soler MV, Qian J, Jiang Z, Johnston RJ Jr, Blackshaw S, Singh MS. Single-cell transcriptome analysis of xenotransplanted human retinal organoids defines two migratory cell populations of nonretinal origin. Stem Cell Reports. 2023 May 9;18(5):1138-1154. doi: 10.1016/j.stemcr.2023.04.004. PMID: 37163980; PMCID: PMC10202694.

Mandeep Singh, MD,PhD

Chief, Division of Ocular Immunology & Uveitis
Professor of Ophthalmology
Wilmer Eye Institute, Johns Hopkins University School of Medicine

Narrative Biography

Mandeep S. Singh, MBBS FRCSEd DPhil holds the Andreas C. Dracopoulos Professorship of Ophthalmology and is Associate Professor of Ophthalmology and Genetic Medicine at the Johns Hopkins Wilmer Eye Institute. He is a vitreoretinal surgeon and a clinician-scientist focusing on hereditary retinal diseases. He co-directs the Johns Hopkins Genetic Eye Diseases (GEDi) Center, helping to coordinate multidisciplinary care and research involving patients with hereditary retinal diseases. He is the Study Chair of the Foundation Fighting Blindness (FFB) Consortium's Gyrate Atrophy Ocular and Systemic (GYROS) Study, a prospective international natural history study focusing on the retinal and metabolic consequences of pathogenic variants in the ornithine aminotransferase gene. In addition, he is a member of the FFB Regulatory Endpoints and Trial Design for Inherited Retinal Diseases (IRDs) Working Group, aiming to identify recommendations and engage regulatory bodies regarding the design of IRD clinical trials. In his translational neuroscience laboratory, his team focuses on retinal cell therapy, specifically on photoreceptor transplantation and cellular materials transfer as approaches to promote visual recovery in animal models of hereditary retinal diseases. He also leads a multidisciplinary team to develop image-guided surgical tools to enable targeted and contained delivery of cell- and gene-based therapeutic agents to the retina.

Contact Information

Jthorne@jhmi.edu

Wilmer Eye Institute
Johns Hopkins University
School of Medicine

References

- Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, Acharya NR, Kempen JH, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019 Feb;126(2):283-295. doi: 10.1016/j.ophtha.2018.08.021. Epub 2018 Sep 27. PMID: 30269924; PMCID: PMC6348060.

- Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:; Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE, Thorne JE, Altaweel MM, Kempen JH, Jabs DA. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. doi: 10.1016/j.ophtha.2023.04.011. Epub 2023 Jun 13. PMID: 37318415; PMCID: PMC10524707.

- Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group; Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May;132(5):527-537. doi: 10.1016/j.ophtha.2024.11.021. Epub 2024 Nov 28. PMID: 39612949; PMCID: PMC12018142.

FUTURE VISION FORUM

Jennifer Thorne, MD, PhD

Chief, Division of Ocular Immunology & Uveitis
Professor of Ophthalmology
Wilmer Eye Institute, Johns Hopkins University School of Medicine

Narrative Biography

Jennifer Thorne, M.D., Ph.D., is the Cross Family Professor of Ophthalmology at the Wilmer Eye Institute, where she is also chief of the Division of Ocular Immunology and Uveitis. Prof. Thorne holds a joint appointment as professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health.

An internationally recognized and board-certified ophthalmologist, Prof. Thorne is an expert in the evaluation and management of patients with uveitis and other related immune-mediated disorders. She has published over 300 articles and book chapters on uveitis and ocular immunology, won approximately 30 scientific and clinical awards, and has participated in numerous uveitis clinical trials.

Prof. Thorne's research interests include posterior uveitis including birdshot chorioretinitis, multifocal choroiditis and punctate inner choroiditis. She also studies juvenile idiopathic arthritis-related uveitis, mucous membrane pemphigoid, and treatment outcomes of immunosuppressive drug therapy.

Dr. Thorne is active in national and international ophthalmology and uveitis-related forums, for example, she was President of the American Uveitis Society and remains part of its leadership team, was a member of the Executive and Steering Committees of the Standardization of Uveitis Nomenclature (SUN) Working Group and played advisory and editorial roles in the American Academy of Ophthalmology, Ocular Immunology and Inflammation journal, and more. She has also served as an advisor and consultant for ophthalmic pharma companies, such as Allergan, AbbVie, Gilead, and Merck.

Prof. Thorne received her M.D. degree from the University of Virginia and completed her ophthalmology residency at the University of Pennsylvania's Scheie Eye Institute. She completed her uveitis fellowship at Wilmer and completed her Ph.D. in epidemiology at the Johns Hopkins Bloomberg School of Public Health.

Future Vision Foundation

Contact Information

demetrios_vavvas@meei.harvard.edu

Harvard University

References

- Shah SH, Lu ES, Ploumi I, Hoyek S, Nodecker K, Gumustop S, Wagner SL, Ding X, Zhu Y, Chen C, A Kim L, Vavvas DG, Miller JW, Husain D, Patel NA, Miller JB. Increasing Incidence of Retinal Vein Occlusion Among Young Adults Following the COVID-19 Pandemic. Ophthalmic Surg Lasers Imaging Retina. 2025 Jul 28:1-5. doi: 10.3928/23258160-20250701-01. Epub ahead of print. PMID: 40711399.
- Ploumi I, Ding X, Romano F, Gan J, Lu ES, Cui Y, Phu K, Zhu Y, Nodecker KN, Shah SH, Ntentakis DP, Garg I, Vingopoulos F, Vavvas DG, Husain D, Kim LA, Patel NA, Miller JB. Associations Between Predominant Peripheral Lesions and Systemic Complications of Diabetes Mellitus. Retina. 2025 Jul 18. doi: 10.1097/IAE.0000000000004620. Epub ahead of print. PMID: 40700655.
- Correa VSMC, Emfietzoglou M, Sakuno G, Naafs R, Miller JW, Charonis A, Vavvas DG. Inner Plexiform Layer Substrata Are Discernible with Commercial OCT and Affected by Aging. Ophthalmol Sci. 2025 Apr 28;5(5):100815. doi: 10.1016/j.xops.2025.100815. PMID: 40688489; PMCID: PMC12271057.

FUTURE VISION FORUM

Demetrios G. Vavvas, MD, PhD

Solman and Libe Friedman Professor of Ophthalmology

Narrative Biography

Demetrios G. Vavvas, MD, PhD is the the Director of Retina Service, the Solman and Libe Friedman Professor of Ophthalmology as well as the Co-Director of the Ocular Regenerative Medicine Institute at Harvard Medical School. He has served as the Director of the Eye Trauma service at the same institution. He is also Visiting Professor at the Aristotle University of Thessaloniki and serves in the board of directors of that University.

Dr. Vavvas' work focuses on macular and other retinal degenerations. In clinical research he has actively investigated the role of high dose statins in AMD and has shown that so called non-responders to anti-VEGF in nvAMD are in reality short term responders. He has been active in surgical innovation and was the first to describe minimal invasive surgery for cataract complications, trauma and IOFB and has won the 2022 Kreissig Award for Excellence in Retinal Surgery by ARVO Foundation for Eye Research. He is especially involved in research of cell death mechanisms and neuroprotection strategies and his lab identified receptor interacting protein kinases (RIPK) mediated programmed necrosis as significant mode of photoreceptor cell loss and showed that simultaneous inhibition of both RIP kinase and caspase pathways is necessary for effective neuroprotection.

His research has been funded from multiple sources such as Research to Prevent Blindness, Alcon Research Institute, the National Eye Institute, and several foundations. He has won multiple awards, has published more than 300 peer reviewed manuscripts and several book chapters. His work has resulted in 12 patent fillings with 7 issued and 5 pending with 2 of them licensed to startup companies.

Future Vision Foundation

FUTURE VISION FORUM

2025

Future Vision Forum

Sponsors

Apellis

aura

BAUSCH + LOMB

FOUNDATION FIGHTING BLINDNESS

Future Vision Foundation

FUTURE VISION FORUM

The Future Vision Foundation

Future Vision Foundation (FVF) is an independent 501(c)3 not-for-profit organization. Founded in 2017 by Dr. Suber Huang . The Foundation's mission is to drive progress in vision research by uniting global experts for collaboration, and to showcase breakthroughs though powerful and inspiring films

The Foundation furthers the awareness and advancement of sight-saving research through the annual convening of the Future Vision Awards and Future Vision Forum. The Future Vision Awards (art) is a cinematic celebration honoring individuals' medical breakthroughs in sight by highlighting their extraordinary research and its impact on vision care. The Future Vision Forum (science) is an unparalleled multidisciplinary symposium uniting visionary leaders worldwide to catalyze emerging research and accelerate innovation that improves the lives of people with eye diseases and visual disabilities. Together, the Future Vision Foundation's Awards and Forum aspire to unify art and science to enact unprecedented change in the field of vision.

Future Vision Films

Documentaries created by the Foundation honor pioneers in vision health by delving into their work, illuminating its significance, and demonstrating how it helps people who need it most. Our innovative use of visual arts to tell compelling stories of vision is novel and uniquely powerful. These inspiring films aim to raise awareness about medical advancements and be a catalyst for vision research.

Every year, the Future Vision Awards feature the worldwide debut of Laureate films. Those who receive the Laureate Award are entitled to use their documentary film as a means to share their story, present their research, and promote dialogue that will lead to support for their work.

Future Vision Laureate & Luminary Awards

The Laureate Award is given to individuals who have made remarkable contributions in their field of academic study related to the eye, eye disease, or vision. The awardee's work is recognized as emerging, exceptional, novel, and innovative. Jacque Duncan, MD, Jose Alain Sahel, MD, and Mandeep Singh, MD are the 2025 recipients of this prestigious award.

The Luminary Award acknowledges an individual or organization's exceptional support of vision research or patient care. This year's winner is Geoff Tabin, MD , Himalayan Cataract Project. Previous honorees include Lulie and Gordon Gund of the Foundation Fighting Blindness, Dr. Hunter Cherwek of ORBIS International, Rebecca Alexander of the Usher Syndrome Society, Bradford and Bryan Manning of Two Blind Brothers and David Pyott of the David and Molly Pyott Foundation.

Future Vision Forum

The Future Vision Forum (Forum) is a first-in-kind annual scientific meeting chartered under the Future Vision Foundation.

Faculty participants are visionary leaders in ophthalmology, visual science, and allied fields that share basic science, translational, and clinical viewpoints on the most critical topics of emerging research.
This multidisciplinary approach fosters ideas, programs, and collaborations that result in highly focused and strategic viewpoints that accelerate innovation, discovery, and improve the lives of people with eye disease and visual disability.

The Forum is a strategic, think-tank-style meeting limited to only 50 invitees. Faculty participants engage in moderated panel discussions that foster brainstorming and unique research collaborations. Each year, a major Forum award is conferred. The inaugural recipient was Dr. Michael Chiang, Director of the National Eye Institute/NIH.

Future Vision Foundation

FUTURE VISION FORUM

2025
Future Vision Forum

Future Vision Foundation

Future Vision Foundation

FUTURE VISION FORUM

The Foundation

The Board

Dr. Suber Huang, MD, MBA - Founder/ President
Johnathan Bridge - Vice President
Rozanne Oriella - Board Chair
Laura Cox- Treasurer
Allison Girvin - Secretary
Sung Cha
Margaret Fulton Mueller
Terry Moir
Nicholas Ruthmann, MD, MPH

Staff

Jessica Pietropinto, Executive Director

The Forum

The Scientific Committee

Jean Bennett, MD, PhD
Catherine Bowes Rickman, PhD
Anne L. Coleman, MD, PhD
Jacque Duncan, MD
Suber S. Huang, MD, MBA
Mark Humayun, MD, PhD
Carol Shields, MD
Mandeep Singh, MBBS, MD, PhD
Daniel Ting, MD, PhD

Moderators

James P. Dunn, MD
Carol Shields, MD
Jose Alain Sahel, MD
Suber S. Huang, MD, MBA

Future Vision Foundation

FUTURE VISION FORUM

2025
Future Vision Forum

Previous Awardees

The Luminary Award is the Foundation's highest award and it's bestowed each year to the individual or organization for extraordinary commitment to supporting vision research clinical care or patient advocacy

Luminary Award

2025
Dr. Geoff Tabin, Himalayan Cataract Project

2023
Dr. David and Molly Pyott, David and Molly Pyott Foundation

2022
Bradford and Bryan Manning, Two Blind Brothers

2021
Rebecca Alexander, Usher Syndrome Society

2019
Hunter Cherwek, ORBIS

2018
Gordon & Lulie Gund

Click a year to see awardee films from that year

Visit us at
www.FutureVisionFound.org

A Laureate is an individual who works in visual sciences and has made extraordinary contributions to the understanding, treatment or prevention of blindness and vision related conditions.

Laureate

2025
Dr. Jacque Duncan
Dr. Jose Alain Sahel
Dr. Mandeep Singh

2023
Dr. Catherine Bowes Rickman
Dr. Philip Rosenfeld
Dr. Carol Shields

2022
Dr. Baruch Kuppermann
Dr. Christine Curcio
Drs. Jean Bennett & Albert Maguire

2021
Dr. Edwin Stone
Dr. Mark Terry
Dr. Russell Van Gelder

2019
Dr. David Huang
Dr. Johanna Seddon
Dr. Terry Smith

2018
Dr. Mary Elizabeth (ME) Hartnett
Dr. Mark Humayun
Dr. Krzysztof Palczewski

Future Vision Foundation

FUTURE VISION FORUM

2025
Future Vision Forum

Previous Forums

Previous Forum Topics:

2024 Neurolongevity, Neurorestoration, Neuroprotection , Santa Barbara, CA
2023 Rare Diseases , Washington DC
2022 Human Centric Computing , Los Angeles, CA

Anastasios Nikolas Angelopoulos
Mayssa Attar
Petr Baranov
Robert Bell
Jean Bennett
Kapli Bharti
Michael Bonaguidi
Catherine Bowes Rickman
Brian Brooks
Wilson W. Bryan
Wiley Chambers
Hwei-Wuen Chan
Michael Cheetham
Michael Chiang
Vasileios Christopoulos
Dennis Clegg
Anne Coleman
Karl Csaky
Oliver Danos
Jacque Duncan
Daniela Ferrara
Greg Field
John Flannery
Carol Greider
Tony Grover
Alison Hardcastle
Mary Elizabeth Hartnett
Katherine High
Jill Hopkins
Sam Hopkins
David Huang
Suber Huang
Mark S. Humayun
Juan Carlos Izpisua Belmonte
Thomas V. Johnson
Jayashree Kalpathy-Cramer
Rusty Kelley
Spencer Kellis
Szilard Kiss
Henry Klassen
Peter Kuhn
Linda Lam
Erin Lavik
Paek Lee
Kristina Lerman
Bart LeRoy
Yan Liu
Charles Liu
Stan Louie
Keith A. Luhrs
Vinit Mahajan
Jason Menzo
Denise Montell
Sayoko E. Moroi
Robert W. Nickells
Kouros Nouri-Mahdavi
Stephen Odaibo
Steven Ojemann
Steve Pakola
Krzysztof Palczewski
MIchael Pazzani
Mark Pennesi
Karen Petrou
Anderw Pieper
Eric Pierce
Scooter Plowman
Stephen Poor
Teresa Puthussery
T. Michael Redmond
Thomas Reh
Sarah Reisman
Jose Alain Sahel
Amber Salzman
Namrata Saroj
Leslie Saxon
Lukas Scheibler
Cyrus Shahabi
Sika Sheng
Molly Shoichet
Mandeep Singh
Dong Song
Hongman Song
Eric Soscher
W. Daniel Stammer
Edwin Stone
Xinyi Su
Clive Svendsen
Anand Swaroop
Sally Temple
Daniel Ting
Stanislav Tomarev
Karmen Trzupek
Stephen Tsang
Budd Tucker
Sunny Virmani
Sophia Y. Wang
Jennifer Wellman
David Williams
Benjamin Xu
Yelena Yankovskaya
Hussein Yassine
Glenn Yiu
Michael Young
Siamak Yousefi
Don Zack
Marco Zarbin
Qifa Zhou

Future Vision Foundation

E luce, Vita! from light, life!

Future Vision Foundation

FUTURE VISION FORUM